Pfizer tops Q3 forecasts as total COVID vaccine sales soar

By TOM MURPHY
AP Health Writer

Pfizer is hiking sales expectations for its top-selling COVID-19 vaccine again, and its early look at 2022 also falls well above Wall Street forecasts. The drugmaker says it now expects to book about $36 billion in revenue from Comirnaty this year. That’s about 7% higher than what Pfizer forecast in July and more than twice what the company expected at the start of the year. Pfizer says global vaccine sales could total around $29 billion or more in 2022, and there’s room for growth. The company expects to recognize revenue for 1.7 billion doses. It could produce 4 billion.